HTR1A Genotype

Your brain has a brake on its own serotonin. Nerve cells in the brainstem carry a receptor that senses how much serotonin is already out there and slows their own firing in response. One common inherited difference in the gene for that receptor changes how hard the brake gets applied.

That difference is called rs6295, also written C(-1019)G. It's most of the reason this test exists. It won't tell you whether you'll become depressed or which antidepressant to take. What it gives you is one permanent fact about your serotonin machinery, in a field where almost nothing else can be measured directly.

The Brake on Your Serotonin System

HTR1A is the gene for the serotonin 1A receptor. That receptor is a protein on nerve cells that responds to serotonin. Two receptor populations matter. In the raphe nuclei, a cluster of serotonin-producing cells in the brainstem, it acts as a self-monitor: when serotonin activates it, those cells fire less. In the hippocampus, amygdala, and prefrontal cortex, the same receptor is on the receiving end, passing the signal along rather than throttling it.

rs6295 is a single-letter change in a control region of the gene. In lab models, the G version weakens the binding of proteins that turn this gene up or down. The expected pattern is more self-monitoring receptor in the brainstem and less receptor in some signal-receiving regions. That would push the system toward lower serotonin firing. Human imaging partly supports this model, but not cleanly enough to make the result a clinical readout.

One brain-imaging study pooled 62 healthy adults and 19 people with major depression. In the depression subgroup, rs6295 separated receptor-binding patterns across several brain regions. A second brain-imaging study in 46 healthy adults found that the signal depended on BDNF, another nerve-cell gene: people carrying more risk versions across both genes had higher cortical receptor binding than those without that combined pattern.

What the Large Human Studies Found

Across depression association studies, rs6295 estimates range from no clear link to modestly higher odds in some G-related comparisons. That's the pattern. Small and uneven.

Sources, in order: Donaldson et al. 2016; Huang et al. 2004; Reif et al. 2014.

A G result puts you in a group that has shown worse average odds in some psychiatric studies. It does not put you in a diagnosed category, and it does not predict your future. The useful part is the subgroup finding, which suggests this variant may track how fear circuitry behaves and changes with therapy, not just whether you get a label.

Why Big Studies Disagree

One study reported more suicide attempts in GG carriers in one of its two cohorts but not the other. A second study found no link to suicide at all. The resolution isn't that one of them must be wrong. rs6295 turns a dial, it doesn't flip a switch, and whether a small shift in serotonin tone ever surfaces as a diagnosis depends on stress exposure, other genes, ancestry, and how the study defined the outcome. Older studies that tested one gene at a time have replicated unevenly for exactly this reason. Read your result as one input carrying modest weight, not as a risk score.

Antidepressant Response

The most repeated claim about this gene is that C/C carriers respond better to SSRIs, the most commonly prescribed class of antidepressants, and that G carriers respond worse. Some small studies support that claim. In 130 people treated with citalopram, outcome tracked the combination of this gene and the serotonin transporter gene rather than either one alone. But a 2024 meta-analysis of 11 studies found no reliable association between C(-1019)G and antidepressant efficacy across the usual genetic comparisons.

The prescribing guidance that exists for serotonin reuptake inhibitor antidepressants rests mainly on drug-metabolism genes such as CYP2C19, CYP2D6, and CYP2B6. These genes help set how fast you clear a medication. The CPIC guideline also reviewed SLC6A4 and HTR2A, but did not give prescribing recommendations for them. HTR1A is not guideline-backed for choosing or dosing antidepressants.

Panel-based pharmacogenomic testing can produce a modest increase in remission for adults with depression, though the benefit varies by which panel is used. A randomized trial in adolescents found no advantage over usual care. That matters because a broad pharmacogenomic panel and this receptor genotype are answering different questions.

A different measurement of this same gene may be more dynamic. Blood DNA methylation, chemical tagging that can change over time, has tracked early antidepressant response in two studies, and its effect depended on recent life stress. Your fixed genotype is one part of a system that is still moving.

Depression During Interferon Treatment

The place this genotype has behaved most like a predictor is drug-induced depression. Following 139 people with chronic hepatitis C through interferon therapy, the GG genotype, not just one G copy, raised the odds of becoming depressed during treatment. A later 101-person cohort on interferon plus ribavirin linked this gene, along with two other serotonin genes, to how severe depressive symptoms became and to shifts in tryptophan breakdown. Tryptophan is one raw material your body uses to make serotonin.

If you're heading into a treatment known to provoke mood symptoms, that's the scenario where knowing your genotype in advance can change something real: how closely you and your clinician watch for depression in the first months, and how quickly you act on it.

Schizophrenia

In a two-stage Chinese study with separate discovery and replication groups, common variants in this gene and in a related serotonin receptor gene were associated with schizophrenia. The link to impaired executive function in that same study came from the other gene, not this one, which is the kind of distinction that gets flattened when results are summarized.

Pain and the Rest of the Body

Serotonin receptors aren't confined to the brain, and neither are the associations. In 131 African American adults with sickle cell disease, four variants in this gene were associated with acute crisis pain, with the associations concentrated in men when results were split by sex. That is early, condition-specific evidence. It is not a general pain-risk test.

A systematic review of shared genetics between mood disorders and cardiometabolic disease put this gene among 24 whose biology spans both. That's a statement about overlapping pathways, not a finding that your genotype raises your heart or metabolic risk. Nothing in the human evidence supports reading it that way.

When a Genetic Result Can Mislead You

• What the assay covers: a report focused on rs6295 tells you that one common position. Full gene sequencing reads more, but it still does not turn HTR1A into a diagnostic psychiatric test.
• Clinical sequencing and consumer chips differ: a consumer DNA chip checks a fixed list of positions. A clinical-grade result is the better source before you use the result in a medication or family decision.
• Your ancestry changes the context: how common each version of this gene is, and what the studies found, differ across populations. A finding from one ancestry group may not carry the same weight in another.
• Uncertain calls: broad sequencing can return a variant of uncertain significance. That means the lab cannot yet say whether it matters.
• Germline versus acquired findings: this is meant to be a germline result, the DNA you were born with. If two reports disagree, or if the lab flags possible sample mix-up or low call quality, confirm it with a clinical-grade test.

A Result You Only Get Once

You inherited this genotype and you'll have it for life. It reads the same at 25 and at 75, so there's no trend to follow and no reason to repeat the test unless the lab flags low confidence in the call, or your only result came from a consumer chip and you want it confirmed clinically.

What does move is everything the genotype interacts with. Stress load, sleep, medications, whether you're currently in an episode. The research showing that this gene's effect on antidepressant response depended on recent life stress makes the point directly: the same fixed genotype can look different at different points in your life. If you want numbers to track over time, track those inputs and your symptoms, not this.

What to Do With Your Result

If you carry GG or another reported HTR1A risk result and you've had depression or anxiety, the next test to order isn't another look at this gene. It's a drug-metabolism panel that includes CYP2C19, CYP2D6, and CYP2B6. That answers a different and more actionable question: how fast you clear common antidepressants.

A genotype also can't see the ordinary medical causes of low mood and fatigue. A broad blood panel covering thyroid function, B12, and vitamin D belongs in the same workup, because those are the findings that can change treatment this month rather than in theory.

The combination worth acting on is a risk result plus a strong family history plus a run of medications that didn't work. That pattern argues for structured psychiatric care and drug-metabolism testing, not for concluding the gene caused it. A risk result with no symptoms and no family history argues for doing nothing at all, except remembering it if you ever face a treatment known to provoke depression. If your report lists a variant of uncertain significance, bring in a genetic counselor rather than interpreting it yourself.